11 recruiting, 9 not yet recruiting, 3 active not recruiting, 3 completed. 11 Phase 2, 10 Phase 1, 6 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Retinitis Pigmentosa (RP): new trials by email Literature Review of Retinitis Pigmentosa (RP) trials Research Report on Retinitis Pigmentosa (RP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-01 | 2026-10-13 |
| Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa ULREA-PVS-NP - Retinitis Pigmentosa (RP) | Phase 1 | Recruiting | Kyushu University | 21 | 2026-10-01 | 2026-10-07 |
| Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) RTx-015, Sham Control - Retinitis Pigmentosa (RP), Inherited Retinal Diseases | Phase 2 / Phase 3 | Recruiting | Ray Therapeutics, Inc. | 60 | 2026-10-01 | 2026-10-28 |
| Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa UGX202 Injection - Retinitis Pigmentosa (RP) | Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | 12 | 2026-09-28 | 2026-10-02 |
| Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment Active hf-tRNS., Placebo/sham hf-tRNS - Retinitis Pigmentosa (RP), Rod Cone Dystrophy | Not applicable | Recruiting | University of Waterloo | 20 | 2026-07-01 | 2026-07-07 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration PRIMA Products - Stargardt Disease, Retinitis Pigmentosa (RP) | Not applicable | Recruiting | Science Corporation | 5 | 2026-04-22 | 2026-08-17 |
| Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance Transcorneal Electrical Stimulation using the OkuStim System - Retinitis Pigmentosa (RP), Usher Syndrome | Recruiting | Okuvision GmbH | 30 | 2026-04-20 | 2026-05-01 | |
| Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations No Intervention: Observational Cohort - Retinal Degenerations, Retinitis Pigmentosa (RP) | Not yet recruiting | IRCCS San Raffaele | 200 | 2026-01-01 | 2025-12-05 | |
| Wide Field OCTA in Ocular Diseases Age - Related Macular Degeneration (AMD), Diabetic Macular Edema | Not yet recruiting | IRCCS San Raffaele | 200 | 2026-01-01 | 2025-12-30 | |
| UGX202 Injection in Patients With Advanced Retinitis Pigmentosa UGX202 injection - Retinitis Pigmentosa (RP) | Early Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | 6 | 2026-01-01 | 2025-12-31 |
| Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital Enhanced post-diagnostic support, Usual Care - Retinitis Pigmentosa (RP) | Not applicable | Recruiting | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | 80 | 2025-12-01 | 2026-02-10 |
| Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose) - Retinitis Pigmentosa (RP), Rod Cone Dystrophy | Phase 1 / Phase 2 | Recruiting | SparingVision | 27 | 2025-10-08 | 2026-09-08 |
| Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients CTR implantation - Cataract, Retinitis Pigmentosa (RP) | Not applicable | Recruiting | Zhongshan Ophthalmic Center, Sun Yat-sen University | 88 | 2025-08-25 | 2026-04-23 |
| Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases Intravitreal Adalimumab - Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP) | Phase 1 / Phase 2 | Active not recruiting | Centro de Pesquisa Rubens Siqueira | 30 | 2025-07-10 | 2026-10-27 |
| Retinal Investigation Using Optos OCT Device retinal functional imaging - AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP) | Not applicable | Not yet recruiting | Optos, PLC | 120 | 2025-05-01 | 2025-02-25 |
| Functional Assessments in Vision Impairment Retinitis Pigmentosa (RP), Diabetic Retinopathy (DR) | Not yet recruiting | Center for Eye Research Australia | 45 | 2025-04-01 | 2025-04-03 | |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
Showing 20 of 29. Sign in to see all of them.
Retinitis Pigmentosa (29) · Retinal Diseases (6) · Usher Syndromes (6) · Cone-Rod Dystrophies (5) · Retinal Degeneration (5) · Diabetic Retinopathy (4) · Macular Degeneration (4) · Eye Diseases (3) · Retinal Dystrophies (3) · Stargardt Disease (3) · Vision Disorders (3) · Eye Abnormalities (2) · Eye Diseases, Hereditary (2) · Glaucoma (2) · Anetoderma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29) · Genetic Diseases, Inborn (29) · Eye Diseases, Hereditary (27) · Eye Diseases (26) · Retinal Dystrophies (26) · Retinal Degeneration (24) · Retinal Diseases (23) · Nervous System Diseases (8) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Sensation Disorders (8) · Signs and Symptoms (8) · Abnormalities, Multiple (6) · Blindness (6) · Congenital Abnormalities (6)
N-Acetylcysteinamide (1) · retinol acetate (1) · salicylhydroxamic acid (1)
IRCCS San Raffaele (2) · Laboratoires Thea (2) · Nacuity Pharmaceuticals, Inc. (2) · QLT Inc. (2) · SparingVision (2) · Suzhou UgeneX Therapeutics Co., Ltd. (2) · Ace Cells Lab Limited (1) · BlueRock Therapeutics (1) · Center for Eye Research Australia (1) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (1) · Centro de Pesquisa Rubens Siqueira (1) · Jinnah Burn and Reconstructive Surgery Centre, Lahore (1) · Kyushu University (1) · Marta P. Wiącek (1) · Okuvision GmbH (1)
United States (6) · Canada (4) · France (4) · Brazil (3) · Germany (3) · Australia (2) · Belgium (2) · China (2) · Denmark (2) · Ireland (2) · Italy (2) · Netherlands (2) · United Kingdom (2) · Egypt (1) · Japan (1)
Baruch Kuppermann, MD (1) · Benjamin Thompson, PhD (1) · DR. Mike Chan, stem cells expert (1) · David Saperstein, MD (1) · Dr. Ahmed Tamer Sayed Saif, PhD Ophthalmology (1) · Dr. Alaa Abdelkarim Mohammed, MRCPUK Endocirnology (1) · Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology (1) · Dr. Passant Sayed Saif, PhD ophthalmology (1) · Isabelle Audo, Pr (1) · Penelope J Allen, FRACO, FRACS (1) · Rubens C Siqueira, MD,PhD (1) · Sheikh Riazuddin, PhD (1) · Sushanta Mallick (1) · Xuhua Tan, PhD (1)
PMID 32573764, PMID 40339601, PMID 40927136, PMID 42193355
2025 (1)